Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3920405 | 1.00 | NAMPT (0.49) | NAMPTMEN1KMT2AOPRD1PRMT5 | |
| SCHEMBL30069435 | 1.00 | NAMPT (0.49) | NAMPTMEN1KMT2AOPRD1PRMT5 | |
| SCHEMBL15334651 | 1.00 | NAMPT (0.49) | NAMPTMEN1KMT2AOPRD1PRMT5 | |
| SCHEMBL30167033 | 1.00 | NAMPT (0.49) | NAMPTMEN1KMT2AOPRD1PRMT5 | |
| SCHEMBL2081527 | 1.00 | NAMPT (0.49) | NAMPTMEN1KMT2AOPRD1PRMT5 | |
| SCHEMBL30167028 | 0.89 | NAMPT (0.44) | NAMPTMEN1KMT2AOPRD1PRMT5 | |
| SCHEMBL3917500 | 0.89 | NAMPT (0.44) | NAMPTMEN1KMT2AOPRD1PRMT5 | |
| SCHEMBL3917502 | 0.89 | NAMPT (0.44) | NAMPTMEN1KMT2AOPRD1PRMT5 | |
| SCHEMBL30167045 | 0.89 | NAMPT (0.44) | NAMPTMEN1KMT2AOPRD1PRMT5 | |
| SCHEMBL10207322 | 0.87 | NAMPT (0.44) | NAMPTMEN1KMT2AOPRD1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586170-B | Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative | 江苏集萃分子工程研究院有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117586170-A | Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative | 江苏集萃分子工程研究院有限公司 | 2024-02-23 | — | — | CN | claimed |
| EP-0678099-A1 | NEW PEPTIDES | Astra Aktiebolag (SE) | 1995-10-25 | — | — | EP | claimed |
| WO-1994015959-A1 | NEW PEPTIDES | ASTRA AKTIEBOLAG (SE) | 1994-07-21 | — | — | WO | claimed |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-20240316034-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2024-09-26 | — | — | US | disclosed |
| CN-117586170-B | Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative | 江苏集萃分子工程研究院有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117586170-A | Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative | 江苏集萃分子工程研究院有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| US-11497744-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2022-11-15 | — | — | US | disclosed |
| US-11389464-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3189041-B1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-04-28 | — | — | EP | disclosed |
| WO-2002059107-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002036116-A2 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-10 | — | — | WO | disclosed |
| US-5733881-A | Opioid peptide antagonists | ASTRA AB (SE) | 1998-03-31 | — | — | US | disclosed |
| EP-0777682-A1 | NEW OPIOID PEPTIDE ANTAGONISTS | Astra Aktiebolag (SE) | 1997-06-11 | — | — | EP | disclosed |
| US-5602099-A | ANALGESICS, IMMUNOSUPPRESANTS | AKTIEBOLAGET ASTRA (SE) | 1997-02-11 | — | — | US | disclosed |
| WO-1995035316-A1 | NEW OPIOID PEPTIDE ANTAGONISTS | ASTRA AKTIEBOLAG (SE) | 1995-12-28 | — | — | WO | disclosed |
| EP-0678099-A1 | NEW PEPTIDES | Astra Aktiebolag (SE) | 1995-10-25 | — | — | EP | disclosed |
| WO-1994015959-A1 | NEW PEPTIDES | ASTRA AKTIEBOLAG (SE) | 1994-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316034-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | NAMPT 450/4885MEN1 4543/4885KMT2A 4253/4885 |
| US-11389464-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | NAMPT 2147/4885MEN1 3256/4885KMT2A 1050/4885 |
| US-11497744-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | CXCR4, CXCL12, CXCR1 | NAMPT 450/4885MEN1 4543/4885KMT2A 4253/4885 |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | NAMPT 450/4885MEN1 4543/4885KMT2A 4253/4885 |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | CXCR4, CXCR2, CXCR1 | NAMPT 1416/4885MEN1 4454/4885KMT2A 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.